FindTrial
Sign In

Pemazyre 13.5 mg tablets

DRUG2 trials

Sponsors

Incyte Corp., Incyte Corp., Incyte Corp.

Conditions

CholangiocarcinomaMale and female participants at least 18 years of age who are actively receiving treatment with pemigatinib under a parent protocol and receiving clinical benefit and who do not have access to pemigatinib outside of a clinical trial

Phase 2

INCB 54828-801: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
CompletedCTIS2023-503406-36-00
Incyte Corp., Incyte Corp.Male and female participants at least 18 years of age who are actively receiving treatment with pemigatinib under a parent protocol and receiving clinical benefit and who do not have access to pemigatinib outside of a clinical trial
Start: 2021-12-13End: 2023-05-11Target: 4Updated: 2023-06-09

Phase 3

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
CompletedCTIS2024-513513-12-00
Incyte Corp.Cholangiocarcinoma
Start: 2019-01-06End: 2025-06-03Target: 110Updated: 2025-07-23